CAS: 197376-47-9; Ethyl 6-Chloropyridine-3-Acetate
该化合物是一种有机化合物,通过乙酸酯组群连接了氯化的丙烯酮,其结构将电子提取的氯氟化碳组群定位为丙烯酮环上的乙酸替代体.这种特定安排具有某些反应特性.该分子主要作为一个多用途合成中间体.该分子的功能对于通过核循环替代反应进行进一步的研拟很有价值,有可能合成多种异丙环化合物或药物候选体.该酯组群可以被水解或用于其他转化,从而有利于在有机合成中构建复杂的分子结构.
- 英文名称Ethyl 6-Chloropyridine-3-Acetate
- 中文名称2-(6-氯吡啶-3-基)乙酸乙酯
- IUPAC名称ethyl 2-(6-chloropyridin-3-yl)acetate
- 其它别名2-氯吡啶-5-乙酸乙酯; 2-Chloropyridine-5-Acetic Acid Ethyl Ester
- CAS编号197376-47-9
- MFCD编号:MFCD03092921
- 分子式:C9H10ClNO2分子量:199.63
- 产品CID: 1005152
- 产品分类有机原料→分子砌块→芳杂环类化合物→吡啶类化合物
- 相似结构搜索
- 产品信息参考
;;; - InChIKey: HNMKCAOYIPYXRD-UHFFFAOYSA-N
- InChI=1S/C9H10ClNO2/c1-2-13-9(12)5-7-3-4-8(10)11-6-7/h3-4,6H,2,5H2,1H3
- 计算化学: 氢键受体数3.0氢键供体数*可旋转键数3.0
相似化合物
39891-13-9 117528-28-6 717106-69-9物理性质
MSDS等安全信息
上下游产品
3-(2-ethoxy-2-oxoethyl)pyridin-1-ium-1-olate pyridin-3-yl-acetic acid ethyl ester (6-chloro-pyridin-3-yl)-acetonitrile ethanol ethyl (6-tert-butoxycarbonylaminopyridin-3-yl)acetate ethyl 2-(6-benzamidopyridin-3-yl)propanoate 2-(6-benzamidopyridin-3-yl)propanoic acid N-(5-(1-((2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl)methylamino)-1-oxopropan-2-yl)pyridin-2-yl)benzamide合成工艺路线路线简述
📜3-吡啶乙酸乙酯置于间氯过氧苯甲酸,三氯氧磷体系中,用 氯仿 用作溶剂,化学反应 27.0H,反应生成2-氯吡啶-5-乙酸乙酯
参考文献:The Synthesis Of Thienopyridines From Ortho-Halogenated Pyridine Derivatives; Part 2
标题:The Synthesis Of Thienopyridines From Ortho-Halogenated Pyridine Derivatives; Part 2
摘要:邻卤代吡啶衍生物,2-和4-氯-3-吡啶基乙酸乙酯,3-溴-4-吡啶基乙酸乙酯和3-溴-2-吡啶基乙酸乙酯(其具有通过酯官能团活化的亚甲基)的合成路线为报道称.这些吡啶与二硫化碳在氢化钠存在下反应,然后用碘甲烷猝灭,导致以中等产率形成相应的噻吩并吡啶.
Doi:10.1055/s-1997-1289
海关参考信息
- 2909110000-乙醚
2912110000-甲醛
2912120000-乙醛
2915110000-甲酸 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2010004245-A1
优先权日:2006-10-20
标 题:Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
发明人：OBALLA RENATA M; DESCHENES DENIS; GAGNON MARC; LEBLANC YVES; POWELL DAVID; RAMTOHUL YEEMAN K
权利人:MERCK FROSST CANADA LTD
摘要:Azacycloalkane derivatives of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.
